Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...

Blood cancers account for about 10 percent of new cancer cases each year. While the cause for most is unknown, research and treatments are improving rapidly.

Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...

The 21st annual meeting of the International Myeloma Society takes place September 25-28, 2024, in Rio de Janiero, Brazil.

The Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab-irfc) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with newly diagnosed ...

ImpriMed Unveils Cancer Treatment Prediction Technology at EHA-SfPM Meeting, Expands AI-Driven Precision Medicine Services ...